Headshot of Matthew Zinder

Matthew Zinder, M.S., serves as the Vice President of Regulatory Affairs, overseeing interactions with health agencies such as the FDA and EMA to align on the drug development data for the marketing of Spyre’s products. Mr. Zinder has a broad background in the pharmaceutical industry, encompassing roles in drug and biologics manufacturing, preclinical research, and clinical trials. Most recently, he held the position of Senior Director of Regulatory Affairs at Sierra Oncology. Here, he assumed a leadership role in a cross-functional team that developed OJJAARA (momelotinib), culminating in Sierra Oncology's acquisition by GSK where he continued to lead the program through US marketing approval. Prior to this, Mr. Zinder held roles in regulatory affairs and drug development at Aimmune Therapeutics, Aerami Therapeutics, Insite Vision, Dow Pharmaceutical Sciences, and Bayer Pharmaceuticals. In these experiences, he played a role in achieving the US marketing approval for five novel drugs and/or biologics. In addition, he facilitated global approvals spanning North America, South America, Europe, and Asia, and supported US and global clinical research aimed at advancing safer and more effective medicines. Mr. Zinder holds an M.S. in translational medicine, earned through a joint program between University of California, Berkeley and University of California, San Francisco’s medical school, as well as a B.A. in biochemistry from UC Berkeley.